GTJA released a Research Report stating that the bidding for the third batch of national Chinese Patent Medicine centralized procurement has opened, and the reduction was slightly beyond expectations. Currently, the centralized procurement of Chinese Patent Medicine is still in the early stages, and improvements and expansions are expected to continue. The centralized procurement has reduced companies' marketing costs, which is beneficial for eliminating unreasonable 'water' in the pharmaceutical distribution links, enhancing Industry concentration, and promoting the innovative development of Chinese Patent Medicine.
国泰君安：中成药集采仍处早期阶段 提质扩面有望持续推进
GTJA: The centralized procurement of Chinese Patent Medicine is still in the early stages, and quality improvement and expansion are expected to continue to progress.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.